Urinary Incontinence Drugs Market Size and Share Outlook Report: Forecast Trends and Growth Analysis (2026-2035)

Urinary Incontinence Drugs Market Overview

Urinary incontinence drugs are pharmaceutical treatments designed to manage involuntary urine leakage by improving bladder control and reducing urinary urgency. These medications include anticholinergics, beta-3 adrenergic agonists, and hormone therapies, commonly used for stress, urge, and mixed incontinence. The market is poised to grow at a CAGR of 7.00% during the forecast period of 2026–2035, driven by the rising geriatric population, increasing prevalence of chronic conditions like diabetes and obesity, and growing awareness about urinary health. Advancements in drug formulations and expanding access to healthcare further support market expansion.

Urinary Incontinence Drugs Market Growth Drivers

Generic Drug Penetration to Strengthen Market Growth 

The rising demand for affordable and effective therapies continues to drive growth in the urinary incontinence drugs market across the eight major regions. For instance, in June 2019, Lupin received U.S. FDA approval for its Mirabegron  Extended-Release Tablets, 25 mg and 50 mg, indicated for overactive bladder (OAB) with symptoms such as urge urinary incontinence and urgency. Following this, in April 2024, Lupin launched Mirabegron  Extended-Release Tablets, 25 mg in the United States, after final FDA approval, as a generic version of Astellas Pharma’s Myrbetriq®. This strategic development strengthens treatment access and reinforces the growing role of generics in global market expansion.

Urinary Incontinence Drugs Market Trends

The market is witnessing several trends including expanding indications for beta-3 agonists and rapidly aging population, among others.

Expanding Indications for Beta-3 Agonists to Elevate the Market Value

The market is increasingly driven by the expansion of approved indications for beta-3 adrenergic receptor agonists, targeting broader patient populations. In May 2024, Sumitomo Pharma America advanced this trend by submitting a supplemental New Drug Application (sNDA) for vibegron (GEMTESA®) to the U.S. FDA, aiming to treat overactive bladder symptoms such as urge urinary incontinence, urgency, and urinary frequency, in men  receiving pharmacological therapy for benign prostatic hyperplasia. Supported by successful Phase 3 results, this strategic development highlights a shift toward more tailored and combination-targeted therapies, reinforcing the upward trajectory of market growth.

Rapidly Aging Global Population Expected to Boost Urinary Incontinence Drugs Market Demand

The growing prevalence of an aging population is emerging as a key factor in the expansion of the urinary incontinence drugs market. This trend reflects the increasing need for effective bladder control therapies as older individuals face higher risks of incontinence. In October 2023, the World Health Organization (WHO) highlighted tha t the population aged 60 years and older will double by 2050, reaching 2.1 billion, with the number of individuals aged 80 years and above projected to triple to 426 million. Furthermore, the Population Reference Bureau reported that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by  2050, increasing their share of the population from 17% to 23%. These developments underscore the expanding patient base and are expected to significantly propel the urinary incontinence drugs market forward.

Urinary Incontinence Drugs Market Share

Stress Incontinence to Lead the Market Segmentation Based on Incontinence Type

The market, by incontinence type, is categorized into urge incontinence, overflow incontinence, stress incontinence, mixed incontinence, and others. Among these, the stress incontinence segment is projected to lead the market in the coming years. This trend is primarily driven by the high prevalence of stress urinary incontinence (SUI), particularly among aging women, and the growing demand for safer, non-surgical treatment alternatives. In July 2024, a clinical trial published in The Journal of Urology® introduced TAS-303, an investigational drug that demonstrated  significant efficacy and safety in treating women with SUI. Unlike other drugs, which are associated with gastrointestinal and neurological side effects, TAS-303 is a highly selective noradrenaline reuptake inhibitor that avoids these adverse reactions. The study showed a 58% reduction in SUI episode frequency in the TAS-303 group, with benefits observed as early as four weeks into treatment. Such promising developments are expected to reinforce the dominance of the stress incontinence segment, supported by an aging global population and the increasing preference for pharmacological therapies over surgical procedures.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Urinary Incontinence Drugs Market Analysis by Region

The report covers key regions including the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India, with market expansion driven by an aging population and evolving regulatory frameworks. The United States is expected to lead the market due to its high disease prevalence and supportive regulatory environment. According to Stephen W. Leslie et al. (2024), approximately 13 million individuals in the U.S. are affected  by urinary incontinence, with prevalence rates exceeding 75% among long-term care residents. Regulatory advancements also support market growth, for example, in December 2024, the U.S. FDA approved GEMTESA® (vibegron) by Sumitomo Pharma America, the first β3 agonist approved for men with overactive bladder symptoms u ndergoing treatment for benign prostatic hyperplasia. These developments underscore the region’s momentum in addressing unmet needs and advancing therapeutic options.

Leading Players in the Urinary Incontinence Drugs Market

Other key players in the market are Astellas Pharma, Sanofi S.A., Kyorin Holding, Urovant Sciences, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, and Ferring Pharmaceuticals.

Urinary Incontinence Drugs Market Segmentation

Key Questions Answered in the Urinary Incontinence Drugs Market

• What was the urinary incontinence drugs market value in 2025?
• What is the urinary incontinence drugs market forecast outlook for 2026-2035?
• What major factors aid the demand for the urinary incontinence drugs market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major urinary incontinence drugs market trends?
• Which incontinence is projected to lead the market segment?
• Which drug type is expected to dominate the market segment?
• Which gender is anticipated to drive the market segment?
• Which distribution channel is likely to dominate the market segment?
• Who are the key players in the urinary incontinence drugs market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Urinary Incontinence Drugs Market Report Snapshots

Urinary Incontinence Drugs Companies